Is pemetinib/pemetinib marketed in China? Are there any major domestic hospitals?

Pemigatinib/Pemigatinib has been launched in China. Specifically, this drug was approved by the National Medical Products Administration in April 2022 for the treatment of adult patients with advanced, metastatic or unresectable cholangiocarcinoma (CCA) who have received at least one previous systemic therapy and have been confirmed to have FGFR2 fusion or rearrangement. This means that patients who meet these conditions can use this drug for treatment in China under the guidance of a doctor.

As for whether pemetinib is available in major domestic hospitals, generally speaking, large general hospitals or related cancer hospitals will have a good supply of the drug. However, specific hospitals and drug supply conditions may vary depending on region, hospital level, drug procurement and other factors. Therefore, it is recommended that patients or family members consult with local hospitals or pharmacies to learn about the specific drug supply when they need to use this drug.

The launch of pemetinib is of great significance to patients with cholangiocarcinoma. Cholangiocarcinoma is a refractory and high-risk malignant tumor with an extremely high mortality rate. The 5-year survival rate of patients with advanced stages is only about 5%. As a potent and selective oral inhibitor of FGFR subtypes 1/2/3, pemetinib can inhibit the proliferation and metastasis of tumor cells, thereby helping patients control their disease, improve their quality of life, and extend their survival.

In addition, the clinical data of pemetinib also performed well. In a clinical trial for patients with cholangiocarcinoma, the median progression-free survival of patients treated with pemetinib reached 7.2 months, compared with only 1.8 months in the control group. At the same time, the adverse reactions of pemetinib are relatively mild and can be tolerated by patients.